Home › Research › Tau biomarkers
Cerebrospinal Fluid Biomarkers for Alzheimer Disease Among Patients With Dementia
Skillbäck TB, Jönsson L, Skoog I, Blennow K, Eriksdotter M, Zetterberg H, Kern S.. JAMA neurology, 2025-06-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Importance The defining pathological features of Alzheimer disease (AD) may also be contributing factors in other dementias. Objective To examine the prevalence of β-amyloid (Aβ) and tau pathophysiological changes as indicated by cerebrospinal fluid biomarkers, as well as their association with clinical disease progression, across a broad range of dementias. Design, setting, and participants In this cross-sectional study with a duration of 12 years (October 5, 2010, to August 31, 2022), clinical data from the Swedish registry for cognitive disorders and dementia (SveDem) were merged with clinical routine biomarker measurements of the core cerebrospinal fluid biomarkers of AD: Aβ1-42, total tau (t-tau), and phosphorylated tau 181 (p-tau181).
What this study adds
Evidence grade: Low
This is a cross-sectional study. This large cross-sectional study examined how common amyloid and tau changes, measured in spinal fluid, are across a broad range of dementias and how they relate to clinical progression. It is an observational study and does not test any treatment or cure.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Skillbäck, T. B., Jönsson, L., Skoog, I., Blennow, K., Eriksdotter, M., Zetterberg, H., et al. (2025). Cerebrospinal Fluid Biomarkers for Alzheimer Disease Among Patients With Dementia. JAMA neurology. https://doi.org/10.1001/jamaneurol.2025.0693
Vancouver
Skillbäck TB, Jönsson L, Skoog I, Blennow K, Eriksdotter M, Zetterberg H, et al. Cerebrospinal Fluid Biomarkers for Alzheimer Disease Among Patients With Dementia. JAMA neurology. 2025. doi:10.1001/jamaneurol.2025.0693. PMID: 40293734.
BibTeX
@article{skillback2025-40293734,
author = {Skillbäck, T. B. and Jönsson, L. and Skoog, I. and Blennow, K. and Eriksdotter, M. and Zetterberg, H. and Kern, S.},
title = {{Cerebrospinal Fluid Biomarkers for Alzheimer Disease Among Patients With Dementia}},
journal = {JAMA neurology},
year = {2025},
doi = {10.1001/jamaneurol.2025.0693},
pmid = {40293734},
url = {https://doi.org/10.1001/jamaneurol.2025.0693}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Objective To examine the prevalence of β-amyloid (Aβ) and tau pathophysiological changes as indicated by cerebrospinal fluid biomarkers, as well as their association with clinical disease progression, across a broad range of dementias.
- Design, setting, and participants In this cross-sectional study with a duration of 12 years (October 5, 2010, to August 31, 2022), clinical data from the Swedish registry for cognitive disorders and dementia (SveDem) were merged with clinical routine biomarker measurements of the core cerebrospinal fluid biomarkers of AD: Aβ1-42, total tau (t-tau), and phosphorylated tau 181 (p-tau181).
- Participants were individuals with a dementia diagnosis who had a complete set of cerebrospinal fluid Aβ1-42, t-tau, and p-tau measurements registered less than 3 years after the date of diagnosis.
- Data were analyzed from April to November 2023.
Why it matters
This large cross-sectional study examined how common amyloid and tau changes, measured in spinal fluid, are across a broad range of dementias and how they relate to clinical progression. It is an observational study and does not test any treatment or cure.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designcross-sectional
- Evidence strengthLow
How this study scored 49/100
Published in a leading specialty journal, and it is a snapshot of people at one point in time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (JAMA neurology) |
| Journal's citation record | 2 / 4 | JAMA Neurology: journal h-index 235 (OpenAlex, 2026-10-29) |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 17 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 5.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 4 / 6 | Cited 10.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 2 / 4 | Cited 17 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Silke Kern: h-index 39 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 8 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40293734) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 49 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1001/jamaneurol.2025.0693
- PubMed: 40293734
- Original source →
- Free full text: PubMed Central →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 14.
Related studies in Tau biomarkers from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.